戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              CTLs achieve this by forming an immunological synapse wi
2                                              CTLs can directly kill tumor cells in a contact-dependen
3                                              CTLs engaging cognate targets accelerate the recruitment
4                                              CTLs release cytotoxic proteins such as granzymes and pe
5                               Under 5% O(2), CTL TB and EOPE TB lines did not differ, but, under hype
6   We investigate the clonal repertoire of 29 CTL responses against 23 HIV-1 epitopes longitudinally i
7 as enriched in cells expressing PD-1, TIM-3, CTL-associated protein 4 (CTLA-4), or B and T lymphocyte
8 ly correlated with the NIRF signals of Cy5.5-CTLs at targeted tumor tissues in the early stage.
9 ith the intensity of NIRF signals from Cy5.5-CTLs at tumors after 2-3 days post-injection.
10             The labeling efficiency of Cy5.5-CTLs could be readily controlled by changing concentrati
11                           Importantly, Cy5.5-CTLs presented the strong NIRF signals in vitro and they
12                                    The Cy5.5-CTLs showed different therapeutic responses in E.G-7 tum
13 deficient mice, intravenously injected Cy5.5-CTLs were clearly observed at targeted solid tumors via
14 ese different therapeutic responses of Cy5.5-CTLs were highly correlated with the NIRF signals of Cy5
15 stry, resulting in Cy5.5-labeled CTLs (Cy5.5-CTLs).
16 ve immunotherapeutic approaches with BCR-ABL CTLs in Ph(+) ALL.
17 molecules, which is important for activating CTL against viral infections and tumors.
18 llorecognition as an approach for activating CTL capable of recognizing weak or self-antigens in the
19 tiproliferative effect of IFNgamma might aid CTLs in tumor control.
20            These data highlight that not all CTLs expressing PD-1 are dysfunctional; on the contrary,
21 FLs) of species have been proposed alongside CTLs, to better assess the sublethal effects of rising t
22         Through the mapping of cytokine- and CTL-based genetic interactions, together with in vivo CR
23 trengthened the CTL epitope presentation and CTL responses.
24  SBTx and prompt escalation to rituximab and CTL is recommended.
25 sion of individual genes between EOPE TB and CTL TB under 20% O(2), but, a weighted correlation netwo
26 phenotype capable of Th1, follicular Th, and CTL functionalities, yet they are unable to be infected
27 monitoring of PD-L1 positive tumor cells and CTLs with cellular resolution by non-invasive NIR-IIb li
28 egrees of clustering between tumor cells and CTLs, and between tumor cells and HLA-DR(+) macrophages,
29 were secreted per cell for both NK cells and CTLs, but NK cell SMAPs were larger.
30 -gamma secreting total T cells, T-helper and CTLs against both H1N2 and H1N1 SwIV.
31 ression and altered infiltration of TAMs and CTLs as evidenced by immunohistochemical and flow cytome
32                               Newly arriving CTLs augment the chemotactic signal, further acceleratin
33 and its recognition by specific autoreactive CTLs during inflammation.
34 from band edges) from DFT total energy-based CTL and separate DFT + GW calculations.
35 herichia coli (E. coli) were not affected by CTL or APS diets.
36 endence and MxB sensitivity likely driven by CTL escape.
37  cancer-cell-intrinsic evasion of killing by CTLs and we highlight the importance of these effects wi
38 types associated with escape from killing by CTLs.
39 am of CTL epitopes can also be recognized by CTLs, potentially through aberrant translation.
40 a more potent effector function, as shown by CTLs, in vivo assays.
41 onstrate that adoptively transferred (5M)CAR-CTLs can mitigate type I diabetes by targeting autoimmun
42 lls and cytotoxic T helper (T(H)) cells (CD4-CTLs) responding to SARS-CoV-2 and reduced proportion of
43 tivation and expansion of polyfunctional CD8 CTLs and tumor regression.
44 Y-241 enhances autologous MM-specific CD8(+) CTL activity.
45  as increases pDC-induced MM-specific CD8(+) CTL and NK cell activity against autologous tumor cells.
46 action of antigen-specific cytotoxic T cell (CTL) in vivo results in the emergence of resistant cance
47 sists despite HIV-specific cytotoxic T cell (CTL) responses.
48 toantigen epitopes implicated in CD8 T cell (CTL)-mediated beta-cell destruction in type 1 diabetes (
49 g of the TME and unleashed cytotoxic T cell (CTL)-mediated tumor eradication.
50  minimal effect on the cytotoxic CD8 T-cell (CTL) mediated response.
51  degradation and generate cytotoxic T cells (CTLs) against N peptide.
52  enhances the activity of cytotoxic T cells (CTLs) could identify potential targets for immunotherapy
53 in (OVA) antigen-specific cytotoxic T-cells (CTLs) were incubated with N-azidoacetyl-D-mannosamine-te
54                                   During CMV-CTL monitoring using mutated HLA/CMV tetramers selective
55 ity T cells, we observed coappearance of CMV-CTLs with low (CMV tet(low) CTLs) and high tetramer bind
56           These CTL-derived vesicles contain CTL proteins and exhibit markers and size profiles consi
57 significantly higher rates of contralateral (CTL) TLH (p = 0.016).
58                                 In contrast, CTL responses to DC-derived exosomes were significantly
59 ight finisher diets consisting of 4 control (CTL) diets based on SBM with different crude protein (CP
60 lysis were randomized into either a control (CTL, n = 25) and RT group (RTG; n = 30).
61 ed from umbilical cords of EOPE and control (CTL) pregnancies.
62 ed Langendorff-perfused hearts from control (CTL) and heart failure (HF) mice (HF induced by transaor
63 ifferent between the ZO-1cKO versus control (CTL) mice, basally in young or aged mice, or even when h
64 upon antigen stimulation of ARPC1B-deficient CTLs, leading to a progressive loss of CD8+ T cells.
65 locked at an early stage in Flower-deficient CTLs and is rescued to wild-type level by reintroducing
66 hesize that the slow motility mode describes CTLs creating channels through the collagen matrix by de
67 rs and that the fast motility mode describes CTLs moving within these channels.
68 llular Potts model, in both cases describing CTLs that kill target cells.
69 ted with control of HIV in that the dominant CTL response is Env specific, not Gag specific.
70 nsion of E75-specific cytotoxic T cells (E75-CTL).
71 o reasons: First, the killing signal of each CTL gets diluted over several targets and because this d
72 eic, off-the-shelf bank of 330 GMP-grade EBV-CTL lines from specifically consented healthy HCT donors
73  I BL xenografts, decitabine followed by EBV-CTLs results in T-cell homing to tumors and inhibition o
74 lysis by EBV-specific cytotoxic T cells (EBV-CTLs).
75 y) can also induce remissions if initial EBV-CTLs are ineffective.
76 ed EBV-specific cytotoxic T-lymphocytes (EBV-CTLs) can eradicate EBV-associated lymphomas (EBV-PTLD)
77 ycles consisted of 3 weekly infusions of EBV-CTLs and 3 weeks of observation.RESULTSEBV-CTLs did not
78 peutics licensed the bank of third-party EBV-CTLs from Memorial Sloan Kettering Cancer Center in June
79 median of 2 cycles.CONCLUSIONThird-party EBV-CTLs of defined HLA restriction provide safe, immediatel
80 iled rituximab therapy, with third-party EBV-CTLs.
81 ith POD after a first cycle who received EBV-CTLs from a different donor achieved CR or durable PR (6
82                 Secondary treatment with EBV-CTLs restricted by a different HLA allele (switch therap
83                   RPM-induced early effector CTL also contributed to the endogenous antiviral respons
84  a few days, RPM induced very early effector CTL of a distinct phenotype (Ly6A/E(+) Ly6C((+)) KLRG1(-
85 d, whereas cDC1 induced short-lived effector CTL that eventually cleared the virus.
86 for both the normal accumulation of effector CTLs following acute viral infection and the protective
87 ) to selectively induce more potent effector CTLs derived from naive, rather than memory, CD8(+) T ce
88                                    To elicit CTL responses, epitope vaccines go through an epitope pr
89 2 and AMPK as therapeutic targets to enhance CTL activity.
90 V-infected cells was accompanied by enhanced CTL-mediated clearance of infected cells comparable to g
91          In vivo, inhibition of PCs enhanced CTL infiltration in colorectal tumors and increased tumo
92  of BCL-2 antagonism as a means of enhancing CTL immunotherapy in other settings, such as cancer.
93 observed in clones did not have more escaped CTL epitopes than intact proviruses observed as singlets
94 nd the ability of HIV-1 to rapidly establish CTL escape variants presents major hurdles toward this g
95 oromethylketone repressed PD-1 and exhausted CTLs via induction of T-cell proliferation and apoptosis
96            We also observe that pre-existing CTLs within the tumor are sufficient and essential for s
97             SMAPs were rapidly released from CTLs and were autonomously cytotoxic.
98 upramolecular attack particles (SMAPs), from CTLs to target cells.
99 wledge, that both CMV tet(low) and tet(high) CTLs are functional effector T cells differing by prolif
100                   CMV tet(low) and tet(high) CTLs had an identical effector memory CD45RA(-)CCR7(-) a
101 sis revealed that CMV tet(low) and tet(high) CTLs use different TCRs.
102 Ls) and high tetramer binding (CMV tet(high) CTLs) in 53/115 CMV IgG(+) patients stem cell transplant
103 uring multistage killing saturates at higher CTL and target cell densities.
104                                          How CTLs escape unscathed remains a mystery.
105                                 However, how CTLs regulate the termination of granule secretion remai
106 lyze migration trajectories of primary human CTLs.
107 thogens is generally accomplished by immense CTL expansion and activation, which can destroy infected
108                                 Importantly, CTL activated in this manner can break self-tolerance by
109     Genetic stabilization of IFNAR1 improved CTL survival and increased the efficacy of the chimeric
110 ion and apoptosis inhibition, which improved CTL efficacy against microsatellite instable and microsa
111                                           In CTL hearts, 1.4% of myocytes were poorly synchronized wi
112  we reveal independent emergent behaviour in CTL populations attacking tumour masses.
113 ealed that Tregs were critically involved in CTL tolerance.
114 ates were significantly lower in IMB than in CTL (-14% +/- 5%; P < 0.01) and postprandial MitoPS rate
115 ater extent in IMB (-27.9% +/- 4.4%) than in CTL (-14.3% +/- 4.4%; P = 0.043) with no difference betw
116 ates were significantly lower in IMB than in CTL (-22% +/- 4%; P < 0.01) in both LEU and PLA.
117  III were significantly lower in IMB than in CTL (P < 0.05), with no differences between groups.
118 ed two gene modules (CTL4 and CTL9) that, in CTL TB, were significantly linked to extent of TB invasi
119 nological synapse regulate cortical actin in CTLs, providing a potential mechanism through which CTLs
120 tress, decompresses blood vessels, increases CTL infiltration, and decreases immunosuppression in mur
121 e that contains the virus until cDC1-induced CTL are available to eliminate it.
122 ing vaccination strategies aimed at inducing CTL.
123           We quantified whether infiltrating CTLs are capable of controlling tumors through only dire
124  in response to 20 g milk protein ingestion (CTL: -10% +/- 8%; IMB: -15% +/- 10%; P = 0.039), with no
125 ging but valuable model to gain insight into CTL biology.
126               In this study, we investigated CTLs specific for Pol epitopes in the immunogens in trea
127 een protofilaments in vitro FtsZ lacking its CTL (DeltaCTL) shows a dramatically increased propensity
128  click chemistry, resulting in Cy5.5-labeled CTLs (Cy5.5-CTLs).
129 hydrophobic organic charge-transport layers (CTLs).
130 ochondrial function between the control leg (CTL) and the immobilized leg (IMB).
131 was investigated by charge transition level (CTL) calculations for Nitrogen group (N, P, As, Sb) and
132 sholds, termed the 'critical thermal limit' (CTL).
133                     Critical thermal limits (CTLs) are established viability thresholds when studying
134  features a hypervariable C-terminal linker (CTL) and a conserved C-terminal peptide (CTP).
135  intrinsically disordered C-terminal linker (CTL), and a C-terminal conserved peptide (CTC).
136 ppearance of CMV-CTLs with low (CMV tet(low) CTLs) and high tetramer binding (CMV tet(high) CTLs) in
137   These TMPs inhibit cytotoxic T lymphocyte (CTL) activity both in vitro and in vivo, and thus promot
138 oss-presentation and cytotoxic T lymphocyte (CTL) activity.
139 blish optimal CD8(+) cytotoxic T lymphocyte (CTL) memory for pathogens like the influenza A viruses (
140 generation of CD8(+) cytotoxic T lymphocyte (CTL) memory.
141 on or HIV-1-specific cytotoxic T lymphocyte (CTL) pressure shape the provirus landscape, we performed
142         An effective cytotoxic T lymphocyte (CTL) response against intracellular pathogens is general
143 d suppression of the cytotoxic T lymphocyte (CTL) response.
144 ly functional CD8(+) cytotoxic T lymphocyte (CTL) responses against a broad range of epitopes will li
145 sensitivities due to cytotoxic T lymphocyte (CTL) selected differences in Gag sequence but similar co
146 plexes that redirect cytotoxic T lymphocyte (CTL) specificity and function in response to the clonoty
147                      Cytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promi
148 Vaccines that induce cytotoxic T lymphocyte (CTL)-mediated immune responses constitute an important c
149 tuximab (from 2000), cytotoxic T-lymphocyte (CTL) therapy (available in 1999-2004 and from 2011), and
150 tuximab (from 2000), cytotoxic T-lymphocyte (CTL) therapy (available in 1999-2004 and from 2011), and
151              CD8(+) cytotoxic T lymphocytes (CTL) and natural killer cells are the main cytotoxic kil
152 gh CD8(+) antitumor cytotoxic T lymphocytes (CTL) are the preferred effectors of cancer immunotherapy
153 protein 1 (PD-1) on cytotoxic T lymphocytes (CTL) in colon cancer.
154 late that enhancing cytotoxic T lymphocytes (CTL) targeting conserved envelope (Env) regions can elim
155 the ratio of CD8(+) cytotoxic T lymphocytes (CTL) to CD68(+) macrophages both predict disease-specifi
156 hanisms employed by cytotoxic T lymphocytes (CTL) to control tumors will aid in the development of im
157 n and activation of cytotoxic T lymphocytes (CTLs) and CD103+ cross-presenting dendritic cells (DCs),
158 hile v2.2 generated cytotoxic T lymphocytes (CTLs) and cleared virus within 10 days.
159 ytes-including CD8+ cytotoxic T lymphocytes (CTLs) and natural killer cells-and regulated by Runt-rel
160 terfering cytolytic cytotoxic T lymphocytes (CTLs) and NK cell contacts with tumor cells.
161 e formation between cytotoxic T lymphocytes (CTLs) and the target cells they aim to destroy is accomp
162                     Cytotoxic T lymphocytes (CTLs) are thought to arrive at target sites either via r
163              CD8(+) cytotoxic T lymphocytes (CTLs) eliminate virally infected cells through directed
164 lar imaging of CD8+ cytotoxic T lymphocytes (CTLs) in response to anti-PD-L1 therapy.
165                     Cytotoxic T lymphocytes (CTLs) kill infected and cancerous cells.
166                 CD8 cytotoxic T lymphocytes (CTLs) rely on rapid reorganization of the branched F-act
167  vaccine priming of cytotoxic T lymphocytes (CTLs) requires the activity of endogenous DCs, suggestin
168 curs from activated cytotoxic T lymphocytes (CTLs) where they have recently been reported to complex
169                     Cytotoxic T lymphocytes (CTLs) with strong abilities to suppress HIV-1 replicatio
170 de BCR-ABL-specific cytotoxic T lymphocytes (CTLs), endowed with antileukemia activity, from Ph(+) AL
171 killing mediated by cytotoxic T lymphocytes (CTLs), we performed genome-wide CRISPR screens across a
172 specific binding to cytotoxic T lymphocytes (CTLs).
173 umors, they exclude cytotoxic T lymphocytes (CTLs).
174 to evade killing by cytotoxic T lymphocytes (CTLs).
175                     Cytotoxic T-lymphocytes (CTLs) and natural killer cells (NKs) kill compromised ce
176          Endogenous cytotoxic T-lymphocytes (CTLs) may not be adequate because of cellular exhaustion
177     Killer T cells (cytotoxic T lymphocytes, CTLs) maintain immune homoeostasis by eliminating virus-
178 xample, Ptpn2, Socs1 and Adar1) in mediating CTL evasion, and show that the lipid-droplet-related gen
179 e for the BCR or circulating Ab in mediating CTL responses to B cell-derived exosomes was ruled out u
180  the helped vs. unhelped IAV-specific memory CTL phenotype, with the unhelped set showing a more "exh
181 -specific CTL memory, with "unhelped" memory CTL exhibiting intrinsic dysfunction.
182                   In addition, helped memory CTLs express the effector program characteristic of help
183 ection and the protective function of memory CTLs following challenge with an intracellular bacterium
184   Moreover, we identify that unhelped memory CTLs exhibit defects in a variety of energetic pathways,
185                               Primary murine CTLs coordinate their migration in a process reminiscent
186             We demonstrate in primary murine CTLs that the a3-subunit of the vacuolar-type (H(+))-ade
187  safeguard mitochondrial function in nascent CTLs.
188                                Nevertheless, CTLs lacking centrioles did display substantially reduce
189  +/- SEM: -3.6% +/- 0.5%; P = 0.030) but not CTL with no difference between supplementation groups.
190                      Our characterization of CTL function provides a biochemical handle for understan
191                  However, the combination of CTL exhaustion and the ability of HIV-1 to rapidly estab
192  of cellular exhaustion and the evolution of CTL-resistant viruses.
193             Epitope peptides, as a format of CTL vaccines, are being tested preclinically and clinica
194 ed an activation-induced immunodeficiency of CTL activity in ARPC1B-deficient patients, which could e
195 tially alleviates TMP-mediated inhibition of CTL activity, suggesting that the immunomodulatory effec
196                              Introduction of CTL therapy was associated with improved survival.
197 , we show that loss of ARPC1B led to loss of CTL cytotoxicity, with the defect arising at 2 different
198 e of these subsets led to a complete loss of CTL response.
199 rs and in tumors with a greater magnitude of CTL responses.
200 rameterized based on in vivo measurements of CTL infiltration and killing rates applied to EL4/EG7 tu
201            Here, we show that suppression of CTL killing by CD4(+)CD25(+)Foxp3(+) regulatory T cell (
202 scriptome signatures from these two types of CTL responses revealed uniquely expressed gene clusters
203 uses containing lethal mutations upstream of CTL epitopes can also be recognized by CTLs, potentially
204 g priming promotes memory differentiation of CTLs.
205 ay as a conserved mediator of the evasion of CTLs by cancer cells, and show that this pathway is requ
206 cancer cells to orchestrate their evasion of CTLs, and shows that discrete functional modules that co
207 hypotheses regarding the hypervariability of CTLs and compare FtsZs to other bacterial proteins with
208  membrane proteins at the plasma membrane of CTLs, as recycling via the retromer and WASH complexes w
209 n after adoptive transfer of a population of CTLs.
210  lines that were cultured in the presence of CTLs.
211 ficiency of the stochastic search process of CTLs in the ECM should strongly be influenced by a dynam
212 agreed that the low measured killing rate of CTLs in vivo was insufficient to cause tumor regression.
213                  The resulting resistance of CTLs to perforin explains their ability to kill target c
214 rating azide (N(3)) groups on the surface of CTLs via metabolic glycoengineering.
215              Evidently, adoptive transfer of CTLs pre-cultured with TMPs from irradiated breast carci
216 ned a universal CAR-T cell platform based on CTLs engineered to bind a variety of broadly neutralizin
217 t CD4(+) T cell help is required for optimal CTL responses and the establishment of memory, when and
218 during priming, CD4(+) T cell help optimizes CTL memory by creating T(EM) cells with innate and help-
219 Tx and prompt escalation to rituximab and/or CTL is recommended.
220                      In right MTLE patients, CTL hypometabolism was the strongest predictor of an unf
221  individual CG, whereas the number of CG per CTL was unaffected.
222 by enhancing the number of IFNgamma-positive CTLs.
223 tor program characteristic of helped primary CTLs upon recall with MHC class I-restricted antigens, l
224 nation model, both cDC1 and RPM cross-primed CTL efficiently but with distinct kinetics.
225 lymphoid tissue and aim to elicit protective CTL-mediated immunity.
226  to antiviral immunity by generating a rapid CTL defense force that contains the virus until cDC1-ind
227 ts in comparison with control mice receiving CTLs pre-cultured with TMPs from untreated tumor cells.
228 V-CTLs and 3 weeks of observation.RESULTSEBV-CTLs did not induce significant toxicities.
229           Ag-loaded monocytes induced robust CTL responses via Ag transfer to splenic CD8+ DCs in a m
230  microg/g) and equivalent volumes of saline (CTL) were injected respectively to C57BL/6 mice for 6 we
231                In our ABM, we also simulated CTL production of the cytokine IFNgamma in order to expl
232                             Because a single CTL can kill multiple targets, degranulation must be tig
233 e induction and regulation of HIV-1-specific CTL immunity, which is greatly determined by the context
234 hway during MDC1 induction of HIV-1-specific CTL responses inhibited the priming, activation, and dif
235 cause controllers have strong HIV-1-specific CTL responses, had a smaller proportion of intact provir
236 the overall magnitude of memory HIV-specific CTL responses and reversed the exhausted memory phenotyp
237 nfection for the maintenance of IAV-specific CTL memory, with "unhelped" memory CTL exhibiting intrin
238             We further detected NS3-specific CTL activities as well as CD107a expression of effector
239 s as an adjuvant to induce a robust specific CTL response.
240 ccination site promoted the vaccine-specific CTL response by enhancing expansion, short-lived effecto
241 ction of MUP was dependent on virus-specific CTL as deletion of such cells aborted MUP production.
242 cleared following transfer of virus-specific CTL.
243 Our results show that (p190)BCR-ABL-specific CTLs are capable of controlling treatment-refractory Ph(
244 d HIV vaccine-induced subtype C Env-specific CTLs in a macaque subtype B simian-human immunodeficienc
245 d greater frequencies of neoantigen-specific CTLs than soluble vaccines and even 31-fold greater than
246 yses further confirmed that the Pol-specific CTLs could effectively suppress HIV-1 replication.
247 ains unknown whether the Pol region-specific CTLs are equally efficient.
248 es simultaneous generation of tumor-specific CTLs and curtailment of tumor immunosuppressive environm
249             Here we show that VGLL1-specific CTLs expanded from the blood of a PDAC patient could rec
250 re important, exosomes from IL-12-stimulated CTLs directly activated bystander naive CD8(+) T cells t
251 rol exosomes derived from antigen-stimulated CTLs did not.
252       In an adenoviral infection model, such CTL contained the early viral spread, whereas cDC1 induc
253 ishing feature of CD4+ T cells that survived CTL killing.
254                      This work suggests that CTL selection does not significantly check clonal prolif
255       Although we recently demonstrated that CTLs specific for 5 Gag epitopes in the vaccine immunoge
256                         Here, we report that CTLs achieve this via two protective properties of their
257                      These results show that CTLs constantly lag epitope mutation, suggesting that pr
258  with good clinical outcome, suggesting that CTLs specific for these 6 Pol epitopes had a strong abil
259                                          The CTL/macrophage ratio was significantly different between
260                                 Although the CTL and the target cell are both exposed to perforin wit
261 a supports a compact heterodimer between the CTL domains.
262 dings on human cells, free ISG15 boosted the CTL response in vivo via NK cells in the absence of CD4(
263             Here, we describe a role for the CTL of Caulobacter crescentus FtsZ as an intrinsic regul
264 lonal stability and number of clones for the CTL response against an epitope are inversely associated
265 ver, free ISG15 is a potent adjuvant for the CTL response.
266     Accordingly, in full-length Bs-FtsZ, the CTL acts as a spacer that spatially separates the CTP st
267 ions, resolve three bottleneck issues in the CTL epitope presentation pathway: vaccine uptake, phagol
268               The joint contributions of the CTL and CTP make Bs-FtsZ, an enzyme that is only half as
269 stroy is accompanied by reorientation of the CTL centrosome to a position beneath the synaptic membra
270 ape may require coordinated direction of the CTL clonal repertoire to simultaneously block escape pat
271 newly recognized innate route to promote the CTL response.
272 hile we found that Pol peptides promoted the CTL epitope presentation; we also discovered Pol peptide
273 nment-responsive NP further strengthened the CTL epitope presentation and CTL responses.
274 reatments, but it was not different than the CTL diets fed at these CP levels.
275                        We also find that the CTL weakens GTP binding while enhancing the catalytic ra
276           Our in vitro studies show that the CTL weakens the driving forces for forming single-strand
277 target cell membrane is disrupted, while the CTL is invariably spared.
278    Combination of the MIP signature with the CTL/macrophage ratio stratified patients into three risk
279 o demonstrates that without manipulating the CTLs mediated response extensively, it is difficult to t
280 cessarily due to cooperative behavior of the CTLs.
281            Subsequently, azide groups on the CTLs were chemically labeled with near infrared fluoresc
282 opulations could be reengaged to support the CTLs, converting a weak primary antitumor immune respons
283                                        These CTL-derived vesicles contain CTL proteins and exhibit ma
284 xn phosphorylation with saracatinib in these CTL clones also severely compromised their functional ac
285                                        These CTLs rapidly eliminate N-peptide-displaying cells and dr
286                                        Thus, CTLs recognising a cognate target can induce a localised
287 ncreased hemagglutination-inhibition titers, CTL activity, and earlier virus clearance after homologo
288 c resistance of reservoir-harboring cells to CTL killing.
289 itivity or the resistance of cancer cells to CTL-mediated toxicity.
290 mproved economic efficiency when compared to CTL diets.
291 tricular (A-V) block in ZO-1cKO comparing to CTL hearts.
292 the endogenous antiviral response but not to CTL memory generation.
293 ANOG and autophagy involved in resistance to CTL under hypoxia.
294 of CCR2 increased cancer cell sensitivity to CTLs and enabled the cancer cells to induce DC maturatio
295  Ca(2+) signalling in adoptively transferred CTLs enhances T cell activation and IFN-gamma production
296 hromycin (TUL; n = 24); or (3) no treatment (CTL; n = 21).
297 ered in AV nodal cells of the ZO-1cKO versus CTL.
298           VZV-specific cytotoxic T cell (VZV-CTL) and T follicular helper responses to ZVL did not co
299 age, but similar to other Th1 responses, VZV-CTL peak and baseline responses were independently corre
300 roviding a potential mechanism through which CTLs control cortical actin density.

 
Page Top